Lyell Immunopharma, Inc. LYEL
At closeNov 3, 2026, 4:00 PM EST
After hours · Nov 3, 4:00 PM ET
- YTD
- -65.01%
- 1 year
- -34.92%
- Market cap
- 263.92M
- Revenue (ttm)
- 63.00K
- EPS (ttm)
- -12.73
- Shares out
- 292.16M
- Forward P/E
- -0.73
- YTD return
- -65.01%
- 1-year return
- -34.92%
- Volume
- 78.06K
- Avg volume
- 151.38K
- Open
- 10.92
- Previous close
- 10.88
- Day's range
- 10.58 – 11.59
- 52-week range
- 7.20 – 45.00
- Beta
- -0.48
- Analysts
- Hold
- Price target
- 1.00 (-90.7%)
1M +1.72 (+18.96%)
Key statistics
- Enterprise value
- -210.89M
- PEG ratio
- 0.00
- Price / sales
- 2854.84
- Price / book
- 0.30
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 36.00%
- Free cash flow
- -83.12M
- Total cash
- 440.55M
- Total debt
- 58.58M
- Return on equity
- -33.22%
- Short % of float
- 4.36%
- 50-day average
- 1.01
- 200-day average
- 1.68
Analyst view
Consensus: hold
- Strong buy0
- Buy0
- Hold3
- Sell0
- Strong sell1
Next earnings
Consensus EPS estimate -0.13.
Financials — quick view
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 12, 2024 | HC Wainwright & Co. | reit | Neutral | Neutral |
| Oct 30, 2024 | B of A Securities | down | Buy | Underperform |
| Oct 28, 2024 | HC Wainwright & Co. | reit | Neutral | Neutral |
| Aug 19, 2024 | HC Wainwright & Co. | reit | Neutral | Neutral |
| Jun 27, 2024 | B of A Securities | main | Buy | Buy |
| Jun 27, 2024 | HC Wainwright & Co. | down | Buy | Neutral |
About Lyell Immunopharma, Inc.
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- lyell.com
News
Lyell Immunopharma To Participate in November Investor Events 
Down 27% in 4 Weeks, Here's Why Lyell Immunopharma (LYEL) Looks Ripe for a Turnaround 
Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference 
Lyell Immunopharma Completes Transfer For LYL273 Candidate To LyFE Manufacture Center In Washington 
Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer 
This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday 
This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday 
Here Are Thursday’s Top Wall Street Analyst Research Calls: AppLovin, Charles River, Global Payments, HubSpot, Insulet Corporation, Roper Technologies, Sabra Health Care, Western Digital, Zillow Group, and More 
Stifel Initiates Coverage On Lyell Immunopharma with Buy Rating, Announces Price Target of $36 
B. Riley Securities Initiates Coverage On Lyell Immunopharma with Buy Rating, Announces Price Target of $44
Your note
Sign in to keep a note on LYEL — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| HILL STEPHEN J | Chief Operating Officer | Stock Award(Grant) | Feb 8, 2024 | 48,928 |
| KLAUSNER RICHARD | Director | Sale | Aug 14, 2023 | 0 |
| LANG MATTHEW | Officer | Stock Award(Grant) | Feb 8, 2024 | 50,000 |
| LEE GARY K | Officer | Stock Award(Grant) | Feb 8, 2024 | 52,700 |
| NEWTON CHARLES W. | Chief Financial Officer | Stock Award(Grant) | Feb 8, 2024 | 48,729 |
| SEELY LYNN | Chief Executive Officer | Stock Award(Grant) | Feb 8, 2024 | 200,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| MWG Management Ltd | 6.90% | 20,162,332 | 12.41M | Sep 29, 2024 |
| Orland Properties Ltd. | 5.17% | 15,093,969 | 9.29M | Sep 29, 2024 |
| Blackrock Inc. | 4.71% | 13,747,084 | 8.46M | Sep 29, 2024 |
| Vanguard Group Inc | 3.45% | 10,071,482 | 6.20M | Sep 29, 2024 |
| Foresite Capital Management IV, LLC | 2.85% | 8,325,000 | 5.12M | Sep 29, 2024 |
| Wuxi Apptec Co., Ltd. | 2.53% | 7,390,710 | 4.55M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.99% | 5,817,818 | 3.58M | Sep 29, 2024 |
| Price (T.Rowe) Health Sciences Fund | 1.85% | 5,398,783 | 3.32M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.47% | 4,286,388 | 2.64M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.86% | 2,522,865 | 1.55M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.56% | 1,645,833 | 1.01M | Aug 30, 2024 |
| iShares Russell 2000 Value ETF | 0.53% | 1,551,919 | 955.36K | Oct 30, 2024 |